Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bavisant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 11/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bavisant SCHEMBL521755 | 0.99 | HRH3 (1.00) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| Bavisant SCHEMBL29665225 | 0.97 | HRH3 (0.98) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL522796 | 0.95 | HRH3 (1.00) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL1450634 | 0.94 | HRH3 (0.98) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL1449310 | 0.88 | HRH3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| Bavisant SCHEMBL1449946 | 0.88 | HRH3 (0.78) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL1014002 | 0.86 | HPGD (0.86) | HRH3HPGDGAASMN1; SMN2USP2 | |
| SCHEMBL1449644 | 0.85 | HRH3 (0.75) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| Citric Acid SCHEMBL1449579 | 0.84 | HRH3 (0.79) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL13211156 | 0.84 | HPGD (0.73) | HRH3HPGDL3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | claimed |
| EP-4304719-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2024-01-17 | — | — | EP | claimed |
| EP-4251148-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Richter Gedeon Nyrt. (HU) | 2023-10-04 | — | — | EP | claimed |
| WO-2022189531-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2022-09-15 | — | — | WO | claimed |
| EP-4056231-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2022-09-14 | — | — | EP | claimed |
| WO-2022113008-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | RICHTER GEDEON NYRT. (HU) | 2022-06-02 | — | — | WO | claimed |
| WO-2014071194-A2 | METHODS FOR TREATING FIBROMYALGIA | KATZ ROBERT S (US) | 2014-05-08 | — | — | WO | claimed |
| US-20140121193-A1 | METHODS FOR TREATING FIBROMYALGIA | KATZ ROBERT S (US) | 2014-05-01 | — | — | US | claimed |
| CN-101321730-B | Cyclopropylamines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | claimed |
| EP-1948607-B1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-07 | — | — | EP | claimed |
| US-7687499-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | claimed |
| CN-101321730-A | Cyclopropylamines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | CN | claimed |
| EP-1948607-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | claimed |
| WO-2007035425-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | claimed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885HPGD 714/4885L3MBTL3 3455/4885 |
| US-20140121193-A1 | METHODS FOR TREATING FIBROMYALGIA | HTR5A, COMT, HTR4 | HRH3 927/4885HPGD 3455/4885L3MBTL3 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.